Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda.
AMCP webinar that reviewed AMCP’s activity related to preapproval information exchange (PIE) and provided the payer and manufacturer perspective on the important and usefulness of PIE.
AMCP webinar that reviewed AMCP’s activity related to preapproval information exchange (PIE) and provided the payer and manufacturer perspective on the important and usefulness of PIE.
AMCP CEO Blog: The FDA approved 46 novel drugs in 2017, a 21-year high. However, it could take as long as six months for some of these groundbreaking medicines to reach patients.
AMCP CEO Blog: Health care reform historically has one of the most contentious issues on Capitol Hill. The current fight to repeal the Affordable Care Act (ACA) is just the latest in a string of battles that reaches back many decades, including to the founding of Medicare and Medicaid.
AMCP CEO Blog: A recent article in The New England Journal of Medicine (NEJM) caught my attention for a couple of reasons.
AMCP CEO Blog: Whoever said, “May you live in interesting times,” could have been talking about Congressional health care policy debates circa 2017. Never a dull moment!
